Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects and safety of different doses of the investigational drug NNC0662-0419 in adults living with type 2 diabetes. This study compares NNC0662-0419 to semaglutide, an approved treatment for type 2 diabetes, and a placebo. The purpose is to find out if NNC0662-0419 is effective and safe for treating this condition. Participants will receive one of the three treatments NNC0662-0419, semaglutide, or placebo, all given as weekly injections under the skin. The dose of NNC0662-0419 will be gradually increased over time. The study uses a randomized design where the treatment assignment is by chance, and both participants and researchers do not know the group assignments. Throughout the study, participants will attend visits and undergo assessments at various weeks up to week 48. Researchers will measure blood sugar control using glycated hemoglobin HbA1c at weeks 16, 28, and 40, as well as body weight, blood glucose levels, cholesterol, kidney function, and other health markers. Safety will be monitored by recording any adverse events. The total study participation will last several months with regular monitoring.
Actively Recruiting
Researchers are evaluating UBT251, a new medication, in adults with type 2 diabetes to determine its effectiveness and safety. The study compares UBT251 to a placebo and also includes a comparison to semaglutide, an existing treatment for type 2 diabetes. The trial is designed as a phase 2 study to find the appropriate dose and assess treatment impact on blood sugar control. Participants will be randomly assigned to one of four groups receiving UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Each participant will receive their assigned treatment once weekly by subcutaneous injection. The study includes a treatment period lasting up to 40 weeks, with evaluations at various points including weeks 16, 28, and 40. Throughout the study, participants will undergo regular assessments such as measuring glycated hemoglobin HbA1c to track blood sugar levels, body weight, insulin resistance, blood pressure, cholesterol, and kidney function. Safety will be monitored by recording treatment-emergent adverse events up to 46 weeks. The total participation time covers baseline, treatment, and follow-up visits to evaluate the study outcomes comprehensively.
Actively Recruiting
Researchers are studying the safety and effectiveness of zenagamtide compared to semaglutide for treating adults with excess body weight. This Phase 3 trial focuses on participants with overweight or obesity to evaluate how these treatments help with weight loss. Participants are randomly assigned to one of three groups one receiving zenagamtide plus a placebo matching semaglutide, another receiving a lower dose of semaglutide plus a placebo matching zenagamtide, and the last group receiving a higher dose of semaglutide plus a placebo matching zenagamtide. All injections are given subcutaneously once weekly using pre-filled pen injectors in the thigh, abdomen, or upper arm. Participants also follow a reduced-calorie diet and increase physical activity throughout the study. During the 84-week study period, participants will be regularly monitored for changes in body weight and waist circumference. The main outcome is the relative change in body weight from the start to week 84. Safety and adherence will be assessed through scheduled visits where injections, diet, and exercise are reviewed. The study lasts until October 2028, with ongoing evaluations at specific intervals to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of ION775 in adults with hypertriglyceridemia and severe hypertriglyceridemia. This open-label Phase 2 trial aims to assess how ION775 affects fasting triglyceride levels, an important factor in lipid disorders. The study is sponsored by Ionis Pharmaceuticals, Inc. and involves participants with elevated triglyceride levels who are already receiving standard lipid-lowering treatments. Participants are randomly assigned to receive ION775 through subcutaneous injections in one of three dose groups. The study consists of a 4 to 6 week screening period, followed by a 6-month treatment phase where participants receive ION775, and then a 6-month post-treatment follow-up period to monitor outcomes. During these phases, researchers assess changes in fasting triglycerides and other lipid markers. Throughout the trial, participants will undergo laboratory tests to measure triglycerides, apolipoprotein C-III, very low-density lipoprotein cholesterol, remnant cholesterol, and non-high-density lipoprotein cholesterol at baseline and after 6 months of treatment. Safety is monitored by tracking treatment-emergent adverse events and laboratory abnormalities for up to 12 months. The total duration of participation is approximately 12 months, including screening, treatment, and follow-up.
Actively Recruiting
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of D-2570 in adults with moderate to severe plaque psoriasis. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to assess how well D-2570 works and how safe it is for participants with this skin condition. The study focuses on participants who have had stable disease without major flares for at least six months. Participants will be randomly assigned to receive either a low dose or a high dose of D-2570 tablets, or placebo tablets that look identical. Treatments are given over a 12-week period, during which participants and researchers will monitor their responses to the study drug or placebo. The study uses a quadruple-blind design where participants, care providers, investigators, and outcome assessors do not know which treatment is given. During the study, participants will undergo various assessments including measurement of psoriasis severity using the Psoriasis Area and Severity Index PASI, Physicians Global Assessment PGA, and evaluation of body surface area affected. The primary outcome is improvement in PASI-90 after 12 weeks of treatment or placebo. Laboratory tests and safety monitoring will also be performed throughout the study to track any changes and ensure participant safety.
Actively Recruiting
Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.
1-10 of 30
1